ANGPTL3 and coronary artery disorder: Second, although several medications commonly used by patients with CAD may influence the underlying inflammatory and atherosclerotic status, the present study demonstrated that ACEi, ARB, β-blockers, CCB, and fibrates have no impact on circulating ANGPTL3 levels or on new MACE development.